VACCINES: PRODUCTS

Vaccinepipeline

IL1 and IL6 are a major mediators of inflammation, and inflammation is a major component for the persistence of chronic diseases. Our current development focuses on two chronic inflammatory diseases in which the toxic roles of IL1 and IL6 have been demonstrated: rheumatoid arthritis and systemic sclerosis.

 

PPV-06 : Anti-IL-6 vaccine


Peptinov’s anti-IL-6 vaccine is now its most advanced product and is ready for pre-clinical and clinical development.

PPV-06 test results have demonstrated:

– a protective effect in a mouse systemic sclerosis model (published results),

– induction of neutralizing anti-human IL-6 antibodies after immunizations in rabbits,

– induction of significant levels of anti-human IL-6 antibodies and of a protective effect against the inflammation linked to the Delayed-Type Hypersensitivity response in monkeys using a peptide sequence which is identical in monkey and human IL-6 (Desallais et al., Sci Rep, 2016).

Based on these results, Peptinov believes the first human clinical trials for this vaccine can be completed within a 4-year timeframe.

Why IL-6? 

IL-6 is a pro-inflammatory cytokine, whose overproduction has been involved in the pathogenesis of several chronic inflammatory diseases such as rheumatoid arthritis, systemic sclerosis or Horton’s disease.
It has already been validated as a relevant therapeutic strategy with monoclonal antibodies such as Actemra (tocilizumab) sold by Roche, an anti-IL-6R antibody approved for the treatment of rheumatoid arthritis, and sirukumab and siltuximab, anti-IL-6 monoclonal antibodies currently in Phase III clinical development.

PPV-01 : Anti-IL-1b vaccine


IL-1b is a pro-inflammatory cytokine whose overproduction has been involved in the pathogenesis of several chronic inflammatory diseases such as rheumatoid arthritis, CAPS syndromes or atopic dermatitis.
Targeting IL-1b has also been validated as a relevant therapeutic strategy, as demonstrated by the development of anakinra or canakinumab.

PPV-01 test results have demonstrated:
– protective effect in a mouse rheumatoid arthritis model,
– induction of neutralizing anti-human IL6 antibodies after immunizations in rabbits.

Based on these results, Peptinov received grant funding for tests in monkeys, which should end in September 2016 and which should lead to Phase I clinical development by year-end 2017.

 

PPV-03 : Anti-IL-23 vaccine


IL-23 is a pro-inflammatory cytokine whose overproduction has been involved in the pathogenesis of chronic inflammatory diseases such as psoriasis or Crohn’s disease.

The use of ustekinumab for the treatment of psoriasis has validated IL-23 as a relevant therapeutic target. IL-23 is composed of two sub-units: IL-23p19, which is specific to IL-23, and IL-23p40 which is shared by IL-12. 

PPV-03 test results have demonstrated:
– protective effect in a mouse rheumatoid arthritis model
– induction of neutralizing anti-human IL-23 antibodies after immunizations in rabbits

This vaccine is at the same stage of development as PPV-01. Grant applications are underway to fund continued development.